Cargando…

Effects of fructose-containing sweeteners on fructose intestinal, hepatic, and oral bioavailability in dual-catheterized rats

OBJECTIVE: Fructose is commonplace in Western diets and is consumed primarily through added sugars as sucrose or high fructose corn syrup. High consumption of fructose has been linked to the development of metabolic disorders, such as cardiovascular diseases. The majority of the harmful effects of f...

Descripción completa

Detalles Bibliográficos
Autores principales: Villegas, Leah R., Rivard, Christopher J., Hunter, Brandi, You, Zhiying, Roncal, Carlos, Joy, Melanie S., Le, MyPhuong T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6224110/
https://www.ncbi.nlm.nih.gov/pubmed/30408104
http://dx.doi.org/10.1371/journal.pone.0207024
_version_ 1783369544672215040
author Villegas, Leah R.
Rivard, Christopher J.
Hunter, Brandi
You, Zhiying
Roncal, Carlos
Joy, Melanie S.
Le, MyPhuong T.
author_facet Villegas, Leah R.
Rivard, Christopher J.
Hunter, Brandi
You, Zhiying
Roncal, Carlos
Joy, Melanie S.
Le, MyPhuong T.
author_sort Villegas, Leah R.
collection PubMed
description OBJECTIVE: Fructose is commonplace in Western diets and is consumed primarily through added sugars as sucrose or high fructose corn syrup. High consumption of fructose has been linked to the development of metabolic disorders, such as cardiovascular diseases. The majority of the harmful effects of fructose can be traced to its uncontrolled and rapid metabolism, primarily within the liver. It has been speculated that the formulation of fructose-containing sweeteners can have varying impacts on its adverse effects. Unfortunately, there is limited data supporting this hypothesis. The objective of this study was to examine the impact of different fructose-containing sweeteners on the intestinal, hepatic, and oral bioavailability of fructose. METHODS: Portal and femoral vein catheters were surgically implanted in male Wistar rats. Animals were gavaged with a 1 g/kg carbohydrate solution consisting of fructose, 45% glucose/55% fructose, sucrose, glucose, or water. Blood samples were then collected from the portal and systemic circulation. Fructose levels were measured and pharmacokinetic parameters were calculated. RESULTS: Compared to animals that were gavaged with 45% glucose/55% fructose or sucrose, fructose-gavaged animals had a 40% greater fructose area under the curve and a 15% greater change in maximum fructose concentration in the portal circulation. In the systemic circulation of fructose-gavaged animals, the fructose area under the curve was 17% and 24% higher and the change in the maximum fructose concentration was 15% and 30% higher than the animals that received 45% glucose/55% fructose or sucrose, respectively. After the oral administration of fructose, 45% glucose/55% fructose, and sucrose, the bioavailability of fructose was as follows: intestinal availability was 0.62, 0.53 and 0.57; hepatic availability was 0.33, 0.45 and 0.45; and oral bioavailability was 0.19, 0.23 and 0.24, respectively. CONCLUSIONS: Our studies show that the co-ingestion of glucose did not enhance fructose absorption, rather, it decreased fructose metabolism in the liver. The intestinal, hepatic, and oral bioavailability of fructose was similar between 45% glucose/55% fructose and sucrose.
format Online
Article
Text
id pubmed-6224110
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-62241102018-11-19 Effects of fructose-containing sweeteners on fructose intestinal, hepatic, and oral bioavailability in dual-catheterized rats Villegas, Leah R. Rivard, Christopher J. Hunter, Brandi You, Zhiying Roncal, Carlos Joy, Melanie S. Le, MyPhuong T. PLoS One Research Article OBJECTIVE: Fructose is commonplace in Western diets and is consumed primarily through added sugars as sucrose or high fructose corn syrup. High consumption of fructose has been linked to the development of metabolic disorders, such as cardiovascular diseases. The majority of the harmful effects of fructose can be traced to its uncontrolled and rapid metabolism, primarily within the liver. It has been speculated that the formulation of fructose-containing sweeteners can have varying impacts on its adverse effects. Unfortunately, there is limited data supporting this hypothesis. The objective of this study was to examine the impact of different fructose-containing sweeteners on the intestinal, hepatic, and oral bioavailability of fructose. METHODS: Portal and femoral vein catheters were surgically implanted in male Wistar rats. Animals were gavaged with a 1 g/kg carbohydrate solution consisting of fructose, 45% glucose/55% fructose, sucrose, glucose, or water. Blood samples were then collected from the portal and systemic circulation. Fructose levels were measured and pharmacokinetic parameters were calculated. RESULTS: Compared to animals that were gavaged with 45% glucose/55% fructose or sucrose, fructose-gavaged animals had a 40% greater fructose area under the curve and a 15% greater change in maximum fructose concentration in the portal circulation. In the systemic circulation of fructose-gavaged animals, the fructose area under the curve was 17% and 24% higher and the change in the maximum fructose concentration was 15% and 30% higher than the animals that received 45% glucose/55% fructose or sucrose, respectively. After the oral administration of fructose, 45% glucose/55% fructose, and sucrose, the bioavailability of fructose was as follows: intestinal availability was 0.62, 0.53 and 0.57; hepatic availability was 0.33, 0.45 and 0.45; and oral bioavailability was 0.19, 0.23 and 0.24, respectively. CONCLUSIONS: Our studies show that the co-ingestion of glucose did not enhance fructose absorption, rather, it decreased fructose metabolism in the liver. The intestinal, hepatic, and oral bioavailability of fructose was similar between 45% glucose/55% fructose and sucrose. Public Library of Science 2018-11-08 /pmc/articles/PMC6224110/ /pubmed/30408104 http://dx.doi.org/10.1371/journal.pone.0207024 Text en © 2018 Villegas et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Villegas, Leah R.
Rivard, Christopher J.
Hunter, Brandi
You, Zhiying
Roncal, Carlos
Joy, Melanie S.
Le, MyPhuong T.
Effects of fructose-containing sweeteners on fructose intestinal, hepatic, and oral bioavailability in dual-catheterized rats
title Effects of fructose-containing sweeteners on fructose intestinal, hepatic, and oral bioavailability in dual-catheterized rats
title_full Effects of fructose-containing sweeteners on fructose intestinal, hepatic, and oral bioavailability in dual-catheterized rats
title_fullStr Effects of fructose-containing sweeteners on fructose intestinal, hepatic, and oral bioavailability in dual-catheterized rats
title_full_unstemmed Effects of fructose-containing sweeteners on fructose intestinal, hepatic, and oral bioavailability in dual-catheterized rats
title_short Effects of fructose-containing sweeteners on fructose intestinal, hepatic, and oral bioavailability in dual-catheterized rats
title_sort effects of fructose-containing sweeteners on fructose intestinal, hepatic, and oral bioavailability in dual-catheterized rats
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6224110/
https://www.ncbi.nlm.nih.gov/pubmed/30408104
http://dx.doi.org/10.1371/journal.pone.0207024
work_keys_str_mv AT villegasleahr effectsoffructosecontainingsweetenersonfructoseintestinalhepaticandoralbioavailabilityindualcatheterizedrats
AT rivardchristopherj effectsoffructosecontainingsweetenersonfructoseintestinalhepaticandoralbioavailabilityindualcatheterizedrats
AT hunterbrandi effectsoffructosecontainingsweetenersonfructoseintestinalhepaticandoralbioavailabilityindualcatheterizedrats
AT youzhiying effectsoffructosecontainingsweetenersonfructoseintestinalhepaticandoralbioavailabilityindualcatheterizedrats
AT roncalcarlos effectsoffructosecontainingsweetenersonfructoseintestinalhepaticandoralbioavailabilityindualcatheterizedrats
AT joymelanies effectsoffructosecontainingsweetenersonfructoseintestinalhepaticandoralbioavailabilityindualcatheterizedrats
AT lemyphuongt effectsoffructosecontainingsweetenersonfructoseintestinalhepaticandoralbioavailabilityindualcatheterizedrats